References
- Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012;380:1590-605
- Hanauer SB, Feagan BG, Lichtenstein GR, et al; the ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
- Kamm MA, Hanauer SB, Panaccione R, et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease. Aliment Pharmacol Ther 2011;34:306-17
- Lichtenstein GR, Thomsen OØ, Schreiber S, et al; Precise 3 Study Investigators. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600-9
- af Björkesten CG, Nieminen U, Sipponen T, et al. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol 2013;48:543-51
- Kiss LS, Szamosi T, Molnar T, et al; for the Hungarian IBD Study Group. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther 2011;34:911-22
- Smith B, Ceska T, Henry A, et al. Detailing the novel structure of the biopharmaceutical certolizumab pegol [abstract 1102]. Am J Gastroenterol 2008;103:S430
- Cimzia (certolizumab pegol) injection, for subcutaneous use [package insert]. Smyrna, GA: UCB Inc., 2013. Available at: http://www.cimzia.com/assets/pdf/Prescribing_Information.pdf [Last accessed 5 October 2015]
- Sandborn WJ, Feagan BG, Stoinov S, et al; for the PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:228-38
- Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al; for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;357:239-50
- Sandborn WJ, Lee SD, Randall C, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther 2014;40:903-16
- Sandborn WJ, Melmed GY, McGovern DP, et al. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn’s disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther 2015;42:330-42
- Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;1:514
- Wade JR, Parker G, Kosutic G, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn’s disease. J Clin Pharmacol 2015;55:866-74
- Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn’s disease. Inflamm Bowel Dis 2013;19:1112-22
- Iwasa R, Yamada A, Sono K, et al. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterol 2015;15:103
- Lewis JD. C-reactive protein: anti-placebo or predictor of response. Gastroenterology 2005;129:1114-16
- Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn’s Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005;129:807-18
- Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 2015;21:182-97
- Baert F, Vande Casteele N, Tops S, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther 2014;40:1324-32
- Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014;63:1721-7
- Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-9.e3